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Available online 09 November 2016Cardiotoxicity induced by chemotherapeutic agents and radiotherapy is a growing problem. In recent years, an
increasing number of new drugs with targeted action have been designed. These molecules, such as monoclonal
antibodies and tyrosine kinase inhibitors, can cause different type of toxicities compared to traditional chemo-
therapy. However, they can also cause cardiac complications such as heart failure, arterial hypertension, QT inter-
val prolongation and arrhythmias. Currently, a ﬁeld of intense research is the vascular toxicity induced by new
biologic drugs, particularly those which inhibit vascular endothelial growth factor (VEGF) and its receptor
(VEGF-R) and other tyrosine kinases. In this review, we aim at focusing on the problem of vascular toxicity in-
duced by new targeted therapies, chemotherapy and radiotherapy, and describe the main mechanisms and em-
phasizing the importance of early diagnosis of vascular damage, in order to prevent clinical complications.








In recent years, with the introduction of new drugs in therapeutic
regimens, we have assisted to signiﬁcant advances in the treatment of
cancer. Among these drugs, monoclonal antibodies such as trastuzumab,
pertuzumab and bevacizumab, and tyrosine kinase inhibitors-TKI (i.e.
sorafenib, sunitinib, imatinib, lapatinib, axitinib, pazopanib,
cabozantinib) are often used. Such molecules are characterized by a
targeted action [1] on well-known proteins with important roles in can-
cer biology [2]. However, despite their selective action, they can still
cause cardiovascular complications such as arterial hypertension, QT in-
terval prolongation, heart failure (HF), cardiomyopathy, stroke, acute
myocardial infarction (AMI), thromboembolic events and cardiovascular
deaths [3,4] since the same targets also play a role inmaintaining cardio-
vascular homeostasis [5–9].
As their effects on the cardiovascular system are not a so-called
“class-effect”, for themajority of the approved TKIs the risk of signiﬁcanting, Institute of Cardiology, “G.
.cardiotoxicity appears to be low. However, for some of them, this risk
can become signiﬁcant because of their long-term and continued use.
Many studies have focused on the myocardial effects of targeted
therapies. The purpose of this review is twofold, that is to discuss the
major mechanisms of vascular toxicity induced by new targeted thera-
pies in parallel with chemotherapy and radiotherapy, and to highlight
the importance of an early diagnosis of vascular damage, in order to pre-
vent cardiovascular complications.
2. Endothelial function and VEGF
It is nowwell accepted that the endothelium is not a simple cellular
monolayer that separates the blood from vascular walls, but also plays a
key role in maintaining vascular homeostasis, by producing vasocon-
strictor and vasodilator substances, such as endothelin-1 (ET-1), angio-
tensin II (Ang II), thromboxane A2, reactive oxygen species, nitrogen
monoxide (NO) and prostacyclin [10]. The homeostasis of the entire
cardiovascular system is maintained with the help of a healthy endo-
thelium. Mature endothelial cells (ECs), endothelial progenitor cells
and circulating ECs participate in the physiological maintenance of car-
diovascular tissue homeostasis, including vascular tone, permeability
and intima thickness, vessel remodeling and angiogenesis, coagulation
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pathophysiology of several diseases, including atherothrombosis,
diabetes, sepsis, pulmonary hypertension, microangiopathy associated
with neurodegenerative diseases, hepatic steatosis and cancer metasta-
sis [11,12].
Vascular endothelial grown factor (VEGF) is the main member of a
family of structurally and functionally related cytokines, which plays a
critical role in angiogenesis, promote cell survival, and growth and pro-
liferation of endothelial cells by binding to speciﬁc receptors (VEGFR-1,
VEGFR-2, neuropilin) [13,14]. VEGF includes a family of sevenmembers
such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PIGF.
They all have a common homologous domain. VEGF-A is the most rep-
resentative compound. VEGF-A mRNA is expressed in several tissues,
including the lung, kidney, heart and adrenal glands. VEGF-A is a glyco-
protein that exists in at least seven isoforms, from 34 to 42 kDa of mo-
lecular weight, which are derived by alternative splicing of the eight
exons of the VEGF human gene. The monomers consisting of 121, 145,
148, 165, 183, 189 or 206 amino acids and the presence or absence of
the heparin binding domain affects the characteristics of the different
isoforms. VEGF 189 and VEGF 206 bind heparin with high afﬁnity, are
strongly basic and completely sequestered in the extracellular matrix,
while VEGF 121 is a highly diffusible protein. VEGF 165has intermediate
properties.
To date, researchers have identiﬁed three different receptors that
bind VEGF, such as VEGFR-1 (Flt-1), VEGFR-2 (KDR or Flk-1) and
VEGFR-3. The binding of VEGF to its receptors promotes the growth of
vascular endothelial cells derived from arteries, veins and lymphatic
vessels. Each receptor has seven immunoglobulin-like domains in the
extracellular portion, a single transmembrane portion and an intracellu-
lar tyrosine kinase domain. The different receptors differ in activity and
afﬁnity for ligand:
a) VEGFR-1 (Flt-1): it is the ﬁrst VEGF receptor discovered, although its
function is not yet clear. The binding of VEGF-A with this receptor
seems to modulate the division of endothelial cells during the
early stages of vascular development, although with a weak activity
[5,15–17].
b) VEGFR-2 (KDR or Flk-1) appears to be themost important receptor in
the regulation ofmitogenesis and permeability by VEGF. The effects of
VEGF binding to VEGFR-2 during angiogenesis include the production
of platelet activating factor by endothelial cells, stimulation of mitosis
and migration of these cells, as well as an increase in vascular perme-
ability. It has been shown that Flk-1 null mice are characterized by the
absence of vasculogenesis. This evidence highlights the importance of
VEGF binding to VEGFR-2. VEGF binding to this receptor leads to acti-
vation of inositol 3 phosphate kinase, which results in an increase in
intracellular inositol triphosphate. This event leads to activation of
protein kinase B (Akt/PKB) and endothelial nitric oxide synthase.
The ﬁrst enzyme inhibits caspase-9, promotes cell survival, while the
second enzyme leads to NO formation which, in turn, increases the
permeability and cell migration [18].
c) The receptor VEGFR-3 differs from the other two because it moves to-
wards proteolytic cleavage of the extracellular portion. Only VEGF-C
andVEGF-D bind to this receptor, and its presence is limited to the en-
dothelial cells of lymphatic vessels [18–19].
3. Vascular damage caused by VEGF/VEGFR pathway inhibition
Many of the new biological drugs can cause heart and vascular dam-
age. The mechanisms of the underlying cardiovascular toxicity can be
attributed to two main types of toxicity. The ﬁrst is on-target toxicity
(also known as mechanism-based or target related), due to inhibition
of target kinases expressed in other organ systems such as the heart
and vasculature. On-target toxicity typically occurs with imatinib, by in-
hibition of platelet-derived growth factor receptors (PDGFRs), c-kit, Srcfamily member Lck, CSF1R, Cdc2, and discoidin domain receptor
(DDR)1. The second type of toxicity is off-target toxicity. In this case,
cardiovascular toxicity occurs because the drug inhibits a kinase that
is not among its “planned” targets, which, unfortunately, also plays a
key role in heart and vasculature. The inhibition of AMP-activated pro-
tein kinase (AMPK) by Sunitinib is an example of off-target toxicity.
The inhibition of VEGF and its receptors represents a main (but not
sole) mechanism by which antiangiogenic drugs can cause vascular
toxicity [20]. Among them, bevacizumab is a monoclonal antibody that
targets VEGF-A, thus preventing its interaction with VEGFR and leading
to inhibition of tumor angiogenesis. It can cause high blood pressure,
left ventricular dysfunction (LV), HF, myocardial ischemia and
atherothrombotic events (ATEs). The incidence of severe ATEs in pa-
tients treated with bevacizumab was reported at around 1.8%, with an
incidence of AMI equal to 0.6% [21]. Sunitinib is a multi-target TKI. It tar-
gets the VEGF receptor (VEGFR) 1–3, PDGFR, c-Kit, FMS-like tyrosine
kinase-3 (FLT3), colony-stimulating factor-1 receptor (CSF-1R), and
the product of the RET human gene (RET, mutated in medullary thyroid
carcinomas/multiple endocrine neoplasia). It can cause high blood
pressure andHF [22]. Sorafenib is amulti-target TKI that, at clinically rel-
evant concentrations in in vitro kinase assay, inhibits at least 15 kinases,
including VEGFR, PDGFR, Raf-1, B-Raf, c-Kit, and FLT3 [23,24]. It can
cause high blood pressure, myocardial ischemia and rarely HF [25].
Pazopanib is a small molecule, multi-target inhibitor of PDGFR, VEGFR,
and c-KIT. It can cause high blood pressure and congestive HF [26,27].
Axitinib is a potent second generation inhibitor of VEGFR. It can cause
high blood pressure, but also myocardial infarction and arrhythmias
[28]. Regorafenib is a multi-target TKI. It targets VEGFR 2–3, RET, KIT,
PDGFR, and RAF. It can cause high blood pressure andmyocardial ische-
mia [24,29]. Cabozantinib is a potent inhibitor of receptor tyrosine ki-
nases, including VEGF, MET, RET, KIT, Flt-3, AXL and Tie-2. It can cause
venous thrombosis and arterial thrombosis rarely (myocardial infarc-
tion and stroke [30], see Table 3).
In addition, new TKIs are used to treat chronic myeloid leukemia,
such as nilotinib, dasatinib and ponatinib. In particular, nilotinib and
ponatinib can cause cardiovascular toxicity and thrombosis [31].
Nilotinib inhibits Bcr-Abl, PDGF, cKit, BCR-ABL, PDGFR, c-KIT, CSF-1R,
and DDR1. It can accelerate atherosclerosis and peripheral arterial oc-
clusive disease (PAOD), and can determine QTc prolongation [32]. The
exact mechanism is not known. Ponatinib inhibits Bcr-Abl T315I, Src
SFKs, and Src e Lyn. It can cause high blood pressure and cardiovascular
events [33].Dasatinib inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN),
c-KIT, EPHA2, and PDGFRβ. It can cause pleural effusion, heart failure,
and pulmonary hypertension [34].
Overall, there are substantial differences in the incidence of cardio-
vascular side effects of VEGF-inhibitors (i.e., sunitinib - high incidence
- vs. sorafenib - low incidence) and BCR-ABL inhibitors (i.e., ponatinib
- high incidence - vs. nilotinib - low incidence).
VEGF cascade induces proliferation of endothelial cells and promotes
vascular integrity. Hence, inhibition of VEGF/VEGFR signaling pathway
seems to be the main cause of vascular injury, endothelial dysfunction
and atherothrombotic events [35]. In fact, VEGF/VEGFR inhibition can
lead to endothelial dysfunction and exposure of subendothelial colla-
gen. This can facilitate the activation of the coagulation cascade by tissue
factor binding and occurrence of thrombotic events. When VEGF inter-
actswith its receptors VEGFR1, VEGFR2 andVEGFR3, PI3K andphospho-
lipase C (PLC) are triggered. On the one hand, PI3K induces the
conversion of PIP2 into PIP3, which stimulates Akt supported by the ac-
tion of PD1K. Akt then determines the stimulation of eNOS (endothelial
nitric oxide synthase), thus causing the production of NO. On the other
handPLCdetermines the cleavage of PIP2 to inositol trisphosphate (IP3)
and diacylglycerol (DAG). The second messenger IP3 facilitates the
entry of Ca2+ ions in the cell. This can lead to eNOS induction and
increase of NO production. NO can increase cGMP production through
induction of guanylyl cyclase activity. This produces vasodilation with
a reduction of platelet aggregation and smooth muscle cell growth.
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tion and vasoconstriction through the reduction of NO and prostacyclin,
and increase the viscosity of the blood through the overproduction of
erythropoietin. Vasoconstriction is accompanied by endothelial dys-
function. These are two basic elements for creating an altered state of
perfusion. Hence, increased blood viscosity related to cancer, inhibition
of the VEGF/VEGFR and endothelial dysfunction are cardiovascular risk
factors that contribute to increasing the risk of arterial thrombosis
(stroke and myocardial infarction) in cancer patients.
Mechanisms of high blood pressure include both functional (inacti-
vation of eNOS and production of vasoconstrictors such as endothelin-
1) and structural (capillary rarefaction) modiﬁcations [36]. Probably
VEGF-mediated suppression of nephrin, which is important for the
maintenance of glomerular function, can contribute to the development
of arterial hypertension [37]. The loss of pericytes due to inhibition of
PDGFR, along with inhibition of angiogenesis, due to the VEGFR inhibi-
tion, are supposed to be the main mechanisms for capillary rarefaction
[38]. In addition, vascular injury can be “direct”, i.e. caused directly by
the target therapies and VEGF/VEGFR or other inhibitory molecules, or
“indirect” i.e. caused by arterial hypertension secondary to target
treatment.
4. Vascular damage induced by inhibition of other kinases
than VEGFR
PDGFR inhibition is known to impair angiogenesis, and leads to mi-
crovascular dysfunction through the loss of pericytes [39]. This could be
another mechanism related to vascular toxicity induced by sunitinib
and other target drugs. Other molecules involved in angiogenesis
could have important role in the genesis of vascular damage after
their inhibition. For example, some studies have investigated the role
of Notch in the cardiovascular system. Inhibition of Notch is effective
in the oncology setting because it can result in poor highly proliferative
tumor cells and also inhibits the survival of cancer stem cells, which are
considered to be responsible for relapse and metastasis. Furthermore,
since Delta-like ligand 4 (Dll4)-activated Notch signaling is an impor-
tantmodulator of angiogenesis, anti-Dll4 agents are under investigation
to reduce vascularization of the tumor. Notch plays an important role in
the heart during the development and, after the birth, in response to
cardiac damage. Therefore, agents used to inhibit Notch in tumors
(gamma secretase inhibitors and anti-Dll4 agents) could potentially af-
fect myocardial repair. Inhibition of Notch signaling may lead to either
cardiomyocyte or endothelial dysfunction [40]. Notch plays an impor-
tant role in protecting endothelial cells from apoptosis induced by con-
ditions such as inﬂammation, oscillatory blood ﬂow, and ischemia [41].
Another important target is represented by the human epidermal
growth factor receptor-2 (Her-2) also called ErbB2, even if the risk of
signiﬁcant cardiotoxicity by anti-Her-2 drugs appears to be low. ErbB2
is a transmembrane glycoprotein receptor which plays a key role in
cell growth, including myocyte growth, and inhibition of apoptosis
[7–9,42]. Cardiac endothelial cells produce the growth factor NRG1,
which activates the Her-2/Her-4 complex, thus triggering cascades of
ERK–MAPK and PI3K–Akt signaling pathways, promoting cell survival
[43]. Importantly, NRG-1 regulates angiogenesis and NOS-dependent
desensitization of adrenergic stimulation. Trastuzumab treatment acts
on Her-2 reduce survival signals and induce mitochondrial dysfunction
and depletion of energy supplies. In addition, stress factors, such as pre-
vious treatmentwith anthracyclines, increase the production of reactive
oxygen-species (ROS) [44]. Under normal conditions, cells restrict this
event by overexpressing Her-2 and so leading to the activation of the
cell survival pathways. TheHer-2 blockage does not allow the activation
of these pathways that create a state resulting from oxidative stress
leading to apoptosis [5,64,5–51]. Importantly, ErbB2 inhibition has
been also shown to be responsible for a loss of vascular function due
to the reduction in bioavailability of nitric oxide (NO), the increase in
ROS generation and the reduction of survival signals [52,53].5. Vascular damage caused by chemotherapy
Chemotherapy-induced cardiotoxicity has been extensively studied.
Above all chemotherapeutic agents, it is well known that anthracyclines
induce left ventricular dysfunction and HF. Vascular toxicity induced by
chemotherapy is poorly analyzed; however, it can be responsible for in-
creasedmorbidity and/ormortality, thus limiting effectiveness of cancer
therapies. Cancer patients with endothelial dysfunction, may be partic-
ularly susceptible to the adverse effects of anticancer medications. This
is conﬁrmed by the fact that patients treated with cardiotoxic therapies
against cancer, often have multiple risk factors such as hypertension,
obesity, dyslipidemia and metabolic syndrome, which all lead to a
worse vascular reserve, predisposing to endothelial dysfunction and
vascular damage [54].
Endothelial dysfunction can be produced by any chemotherapeutic
agent [55], with many of them involving the production of ROS [56].
For instance, cardiac and endothelial anthracyclines toxicities were at-
tributed to the activation of redox drugs to semiquinone intermediates,
which generate superoxide radicals upon reduction. Both the superox-
ide anion and its dismutation product, hydrogen peroxide, are in fact
toxic for the endothelium [57,58]. Endothelial toxicity induced by
anthracyclines seems to be inﬂuenced by several mechanisms, such as
drug accumulation in the nuclei, mitochondria, DNA repair, stress-
induced signaling mechanisms, the sarcoplasmic reticulum stress,
nitrosative stress, the activity on drug transporters (including MDR1
and MRP1), drug metabolism, and TopI and II inhibition [59,60]. The
latter is a cellular target for anthracyclines. The ubiquitous TopIIb is
expressed in terminally differentiated cells, including adult endothelial
cells; [61] hence it was recently shown that TopIIb could be responsible
for the development of anthracycline-induced endothelial toxicity and
cardiomyopathy [62].
Anthracyclines are also considered to cause negative arterial remod-
eling. As a result, the acute changes in Pulse Wave Velocity [PWV] and
arterial distensibility were observed in breast cancer patients treated
with anthracyclines. In addition, these changes partially reverse after
therapy discontinuation [63]. An increase in arterial stiffness was also
demonstrated in childhood cancer survivors following chemotherapy
[64].
Amongother chemotherapeutic drugs, cisplatin is able to causemyo-
cardial ischemia and tumor apoptosis [65]. Apoptosis is also responsible
for the typical nephrotoxicity, ototoxicity and other cytotoxicities.
Cisplatin-induced cytotoxicity in endothelial cells has been linked to in-
creased generation of procoagulant endothelial micro-particles and free
radicals [66,67]. For example, testicular cancer patients treated with
orchiectomy showed a decrease in plasma levels of the endothelial
pro-thrombotic markers PAI-1 (plasminogen activator inhibitor-1)
and vWF (Von Willebrand factor) compared to those patients
treated with cisplatin [68]. In addition, NO-dependent vasodilation
(ﬂow-mediated vasodilation) seems to be compromised in the long-
term cancer survivors who received cisplatin-based chemotherapy
compared to chemotherapy-naive patients [69].
The chemotherapeutic agent 5-ﬂuorouracil (5-FU) can cause myo-
cardial ischemia and coronary vasospasm is themain underlyingmech-
anism,which has been postulated (Table 1). Its oral form capecitabine is
a prodrug that, after oral intake, is transformed enzymatically to 5-FU by
thymidine phosphorylase. Although capecitabine may have profound
effects on vascular biology, this drug has toxic effects signiﬁcantly less
severe than 5-FU and cardiotoxicity is an uncommon adverse effect.
Other possible mechanisms include endothelial dysfunction with
thrombosis, direct damage of myocytes and hypersensitivity reaction
with Kounis syndrome [70]. Interestingly, 5-FU is able to inhibit angio-
genesis by suppressing the stimulating effect of vascular endothelial
growth factor (VEGF) on the synthesis of DNA during endothelial cells
(EC) mitosis [71]. In addition, it determines endothelial damage with a
ROS-dependentmechanism [72]. Although the inhibition of EC prolifer-
ation during tumor angiogenesis is an important strategy for tumor
Table 1
Vascular toxicity induced by main chemotherapeutics.
Anticancer treatment Vascular toxic effect Mechanism
Anthracyclines Negative arterial
remodeling
ROS, drug-accumulation in nuclei,
mitochondria, DNA repair,
sarcoplasmic reticulum stress,
nitrosative stress, the activity on
drug transporters (including MDR1
and MRP1), drug metabolism,
TopI and II inhibition
5-Fluorouracil Myocardial ischemia Vasospasm (hypothesized cause)
ROS
Cisplatin Myocardial ischemia Cytotoxicity in endothelial cells
with increased formation of
pro-coagulant endothelial
micro-particles and free radicals
Table 2
Vascular toxic effects induced by radiotherapy.
Anticancer treatment Vascular toxic effect
Radiotherapy Stenotic aortic lesion
Accelerated coronary artery disease with
involving of coronary ostia and proximal segments
Carotid lesion
Calciﬁcation of the ascending aorta and aortic arch
Lesions of any other vascular segments present
within the radiation ﬁeld
Table 3
Vascular toxic effects induced by target therapy.
Anticancer
treatment
Vascular toxic effect Target




Sunitinib Arterial hypertension VEGFR1–3, PDGFR/, c-Kit,
FMS-like tyrosine kinase-3
(FLT3), CSF-1R), RET
Pazopanib Arterial hypertension PDGFR, VEGFR, c-KIT.




Regorafenib Arterial hypertension myocardial
ischemia
VEGFR 2–3, RET, KIT, PDGFR,
RAF.
Axitinib Arterial hypertension myocardial
infarction
VEGFR
Cabozantinib Venous thrombosis and rarely
arterial thrombosis (myocardial
infarction and stroke)




disease (PAOD), QTc prolongation.
Bcr-Abl, PDGF, cKit, BCR-ABL,
PDGFR, c-KIT, CSF-1R, DDR1
Ponatinib Arterial hypertension,
cardiovascular events.
Bcr-Abl T315I, Src SFKs, Src e
Lyn.
Dasatinib Pleural effusion, heart failure,
pulmonary hypertension.
BCR-ABL, SRC family (SRC,
LCK, YES, FYN), c-KIT, EPHA2,
and PDGFRβ.
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also hampers endothelial cell homeostasis leading to atherogenesis and
arterial thromboembolic events, which often results in myocardial in-
farction, cerebrovascular insults, and peripheral or mesenteric ischemia
[73–75].
Taxanes are microtubule-binding drugs, whose main mechanism of
action involves the inhibition of cell division, chromatid separation
and growth, ultimately leading to cell death. As with various cancer
cells, taxanes affect the basic functions also of ECs, such as proliferation
and invasion [76]. Moreover, the taxane paclitaxel is also able to en-
hance endothelial tissue factor (TF) expression through its stabilizing
effect on microtubules and activation of c-jun kinase (JNK), with
thrombomodulin down regulating and increased protein nitration
[77]. Vincristine, another tubulin blocker, can adversely affect cardiac
microvascular ECs in rats [78].
Other classical chemotherapeutics, including cyclophosphamide (a
nitrogen mustard inducing DNA alkylation [79]), bleomycin (anti-
tumor antibiotic that induces DNA degradation) and vinca alkaloids
(depolarizing agents causing spiral-like distortions of the cellularmicro-
tubules [80]) have been considered responsible for the endothelial
damage.
6. Vascular damage caused by radiotherapy
Vascular toxicity can also be caused by radiotherapy. This therapeu-
tic approach produces a wide range of deleterious effects on the heart
including pericarditis, coronary artery disease (CAD),myocardial infarc-
tion, valvular heart disease, rhythm abnormalities, no ischemicmyocar-
dial and damage to the conduction system. The risk of cardiovascular
toxicity is increased in thepresence of the following conditions: anterior
or left chest irradiation, high cumulative dose of radiation (N30 Gy),
young age (b50 years), high dose of radiation fraction (N2Gy/day), con-
comitant chemotherapy, cardiovascular risk factors and pre-existing
cardiovascular diseases [81]. Radiotherapy can cause the valve appara-
tus and thickening of the leaﬂet, valvular ﬁbrosis, shortening and calci-
ﬁcation, stenotic aortic lesions, accelerated CAD involving coronary ostia
and proximal segments. Radiotherapy induces extensive lesions, involv-
ing long segments and atypical areas of the carotid arteries. In Hodgkin's
lymphoma, the estimated incidence of vascular lesions (including the
subclavian artery stenosis) is about 7.4%. Radiotherapy can also cause
calciﬁcation of the ascending aorta and aortic arch and other vascular le-
sions inside the radiation ﬁeld (Table 2) [63] and can induce the forma-
tion of atherosclerotic lesions causing narrowing or occlusion of the
vessel. From a microscopic point of view, these lesions are comparable
to those that are not connected to radiotherapy. The induction of the
atherogenic process seems to be accelerated in patients with hypercho-
lesterolemia. The vascular damage induced by irradiation involves the
endothelial cells, the ground substance, elastic lamina, smooth muscle
cells and lysosomal activation. Once these elements are impaired, the
permeability to circulating lipids increases. Furthermore, there is theelastic tissue capability to recover from damage, which determines the
formation of a plaque constituted by ﬁbrosis, including the periarterial
ﬁbrosis, fatty inﬁltration and the heap of macrophage-derived foam
cells, demolition of the intima and calciﬁcation. So, the irradiated arter-
ies show lesions characterized by macrophage-rich nuclei, low collagen
content, and intraplaque hemorrhage. These elements represent a
strong atherogenic stimulus, that leads to the formation of a vulnerable
plaque. As regards the idiopathic atherogenesis, ROS have a role in the
atherogenic process induced by radiations. In fact, the radiolytic hydro-
lysis stimulates the production of different types of ROS, including su-
peroxide anion (O2−) (the major product in the presence of oxygen),
hydrogen peroxide (H2O2) and hydroxyl radical (HO•). Furthermore ra-
diation promotes inﬂammation and thrombosis, supporting ROS pro-
duction, alterations in endothelial cells and, consequently, vascular
damage. It should be noted that together with changes in the endothe-
lial cells, radiation also determines the death of endothelial cells and the
resulting exposure of subendothelial thrombotic factors, thereby facili-
tating vulnerable plaque rupture and thrombotic events (Fig. 1)
[82–84]. In addition, the presence of cardiovascular risk factors (e.g.,
smoking and dyslipidemia) may increase the risk of cardiotoxicity
after radiotherapy [85].
7. Detection and monitoring of vascular toxicity
Since cancer therapies can cause vascular damage through various
mechanisms, it is reasonable to assess vascular function in cancer pa-
tients treated with these drugs. Endothelial dysfunction is an early
step towards more advanced vascular damage and atherothrombotic
events. Some evidence supports the utility of non-invasive assessment
Fig. 1. Vascular damage caused by radiotherapy. Legend: ROS, reactive oxygen species.
15D. Di Lisi et al. / International Journal of Cardiology 227 (2017) 11–17of ﬂow-mediated dilation (FMD = ﬂow hyperemic mediated dilation)
of the brachial artery to detect endothelial dysfunction. This technique
involves measurement of the vessel diameter of the brachial artery at
baseline and after a minute of hyperemic ﬂow, at the peak of mediated
vasodilation by shear stress. Vasodilatation is impaired in case of endo-
thelial dysfunction.
Increased intima-media thickness of the common carotid artery,
measured by ultrasound scan, is a well-known early marker of
atherosclerosis, which signiﬁcantly correlates with the development of
cardiovascular diseases [86,87].
Therefore, carotid ultrasound scan is an easy and inexpensive test
that can be used routinely to assess the onset of atherosclerosis and to
stratify cardiovascular risk especially in intermediate-risk patients.
More recently, great emphasis has been placed on the role of arterial
stiffness (AS) in the identiﬁcation of vascular changes in sub-clinical,
asymptomatic stages. In fact, the increase in stiffness is a very early
sign of vascular damage, earlier than intima media thickening. More-
over, it has already been shown that the PWV is a strong predictor of
overall mortality and cardiovascular events (CE) in both general popu-
lations and hypertensive patients, and that PWVassessment signiﬁcant-
ly improves the risk stratiﬁcation [88]. In clinical practice, there are
three different methods to measure AS: carotid-femoral (cf) PWV, cen-
tral pulse wave analysis and local arterial stiffness. The cf-PWV is con-
sidered as the gold-standard measurement of AS, especially because it
is simple to obtain and because multiple epidemiologic studies have
demonstrated its predictive value for CE. Themain limitation of PWV in-
terpretation is that it is signiﬁcantly affected by high blood pressure
(BP) [89]. Central pulse-wave analysis provides additional information
on wave reﬂections. Local AS can be easily measured on the carotid ar-
teries with ultrasound devices. Echo-tracking devices have been devel-
oped tomeasure end-diastolic diameters and change in diameter with a
very high precision [75]. Local AS can also be evaluated with magnetic
resonance imaging (MRI), but this methodology requires expensive
equipment and a high level of technical expertise. In addition it is not
easily performed in routine settings [90]. Regional AS can be evaluated
with different devices and methods, such as mechanotransducers, to-
nometers, Doppler probes, and echo tracking.
Previous studies assessing cf-PWV and augmentation index have
shown that anti-VEGFR treatment is associated with a marked increasein both brachial and central BP and early aortic reversible stiffening [91].
Speciﬁcally, BP (blood pressure) and cf-PWV, systolic (global longitudi-
nal strain) and diastolic function have been shown to change in patients
after the initiation of the anti-VEGFR treatment. Interestingly, changes
in BP and stiffness seemed to be reversible upon discontinuation of
treatment, while LV systolic and diastolic functions were persistently
abnormal [92].
Arterial stiffness was also increased in patients treated with
anthracyclines. A signiﬁcant increase in aortic stiffness was observed
after 4 months of exposure to anthracyclines [93]. In addition, in child-
hood cancer survivors treated with chemotherapy, AS was increased
compared with patients without cancer [94].
Thus, AS evaluation could be used for early detection of vascular
damage induced by conventional and new antineoplastic drugs and to
accurately stratify CV risk in cancer patients. However, further studies
are needed to determine its true predictive value and usefulness as a
screening tool in this speciﬁc clinical scenario.
8. Strategies to prevent and treat vascular toxicity
Antineoplastic drugs can not only cause cardiac dysfunction but also
vascular injury. Given the high incidence of arterial hypertension in-
duced by VEGF/VEGFR inhibitors, it is very important to control BP be-
fore starting any treatment and accurately monitor its variations
during the course of therapy. It is also mandatory for the control of car-
diovascular risk factors such as diabetes mellitus and dyslipidemia,
which can make patients more prone to vascular injury. Recently, the
importance of monitoring cardiac function by echocardiography,
which is actually recommended after 1 month since starting VEGF or
VEGFR inhibitors and then every 3 months [81], has been emphasized
[95]. On the contrary, there are no standardized guidelines regarding
the monitoring of vascular complications, especially in patients treated
with VEGF/VEGFR inhibitors who are more prone.
We believe that not only cardiac but also vascular function should be
evaluated in cancer patients. An ultrasound of the carotid arteries is
probably the most simple test to perform in routine practice and could
be useful to guide the clinician towards a more efﬁcient management
of cardiovascular risk factors. However, as local AS gives earlier informa-
tion and is therefore worth to be measured, when possible. This
16 D. Di Lisi et al. / International Journal of Cardiology 227 (2017) 11–17approach could reasonably be recommended in patients with risk fac-
tors, together with a thorough echocardiographic assessment. The opti-
mal management of hypertension caused by VEGFR inhibitors remains
controversial, although several potential therapeutic approaches have
been hypothesized [96]. In the absence of speciﬁc data, favorite
antihypertensive agents for the treatment of hypertension in these pa-
tients are ACE-I (angiotensin-converting-enzyme inhibitor) and beta-
blockers, because of theirwell-known cardioprotective effects, although
there are minimal data suggesting superiority of a single class of agents.
Given the hypothesized role for decreased NO signaling in the patho-
genesis of hypertension with these agents, nitrates can be a relevant
mechanistic class of drugs to be used. In addition, nebivolol can enhance
NO signaling, suggesting its therapeutic potential in this population
[97]. Early and aggressive onset of antihypertensive therapy appears
to help the maintenance of the treatment program and to reduce the
risk of major complications, including malignant hypertension and
reversible posterior leukencephalopathy. In patients treated with
VEGF-VEGFR inhibitors it has been recently recommend to: (1) carry
out a formal risk assessment for existing cardiovascular disease and po-
tential cardiovascular complications before treatment, recognizing that
pre-existing hypertension and cardiovascular disease are common in
patientswith cancer, (2) activelymonitor BP elevations and cardiac tox-
icity with more frequent assessments during the ﬁrst treatment cycle,
and (3) aggressively manage BP elevations and early symptoms and
signs of cardiac toxicity to prevent complications of antiangiogenic
drugs [98,99].
9. Conclusions and future directions
Radiotherapy, chemotherapy and target therapies can cause not only
cardiac toxicity but also the vascular toxicity. It is also well known that
because of ventricular-arterial coupling, ventricular and arterial
function is a continuum [100]. Therefore, an overall assessment of
both cardiac and vascular functions, is crucial for cancer patients, to
avoid late complications.
In particular, GLS and PWV measures may add important informa-
tion in the early identiﬁcation of subclinical cardiovascular damage, in
order to promptly initiate any protective treatments and to prevent
future overt damage.
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